Form 4: Catalyst Pharma CSO Vesting & Tax Withholding

Catalyst Pharmaceuticals' Chief Strategy Officer, Preethi Sundaram, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Summary

• Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions on December 8, 2025.
• 6,855 shares of common stock were acquired due to the vesting of restricted stock units.
• 1,669 shares were disposed of to satisfy tax withholding obligations related to the vesting.
• Following these transactions, Sundaram beneficially owns 50,506 shares of common stock directly.
• Sundaram also beneficially owns 805,104 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing is neutral, detailing a routine executive compensation event (RSU vesting and tax withholding) with no significant positive or negative implications for the company's operations or financial health.

Positives

• Vesting of 6,855 restricted stock units indicates continued compensation and retention of a key executive.

Negatives

• Disposition of 1,669 shares for tax withholding reduces the direct shareholding, though this is a standard practice for RSU vesting.

Future Outlook

The filing details a pre-scheduled vesting event for executive compensation, indicating a planned long-term incentive structure for the Chief Strategy Officer.

Industry Context

This is a routine insider transaction filing, common across all industries, reflecting executive compensation practices involving equity awards. It does not provide specific insights into Catalyst Pharmaceuticals' operational performance or industry trends beyond standard executive incentive structures.

Stakeholder Impact

• Shareholders: Minor dilution from the issuance of shares upon vesting, offset by the retention and incentivization of a key executive.
• Employees: Reinforces the company's equity compensation structure for executives.

Next Steps

• The third tranche of restricted stock units is scheduled to vest on December 8, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and subsequent tax withholding. It provides no new information regarding the company's operational performance, financial outlook, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Preethi Sundaram, Chief Strategy Officer, Stock Transaction